Home » Stocks » Brickell Biotech

Brickell Biotech, Inc. (BBI)

Stock Price: $0.915 USD 0.005 (0.51%)
Updated Aug 4, 2020 9:34 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 24.94M
Revenue (ttm) 5.47M
Net Income (ttm) -22.18M
Shares Out 27.27M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $0.915
Previous Close $0.910
Change ($) 0.005
Change (%) 0.51%
Day's Open 0.922
Day's Range 0.910 - 0.935
Day's Volume 36,036
52-Week Range 0.710 - 6.510

More Stats

Market Cap 24.94M
Enterprise Value 17.87M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 27.27M
Float 8.55M
EPS (basic) -5.39
EPS (diluted) -3.17
FCF / Share -4.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 134,439
Short Ratio 0.03
Short % of Float 0.53%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.56
PB Ratio 4.24
Revenue 5.47M
Operating Income -24.00M
Net Income -22.18M
Free Cash Flow -37.43M
Net Cash 7.07M
Net Cash / Share 0.26
Gross Margin -224.77%
Operating Margin -438.60%
Profit Margin -768.00%
FCF Margin -684.08%
ROA -170.77%
ROE n/a
ROIC -180.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$12.60*
Low
12.6
Current: $0.915
High
12.6
Target: 12.60
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.9210.8913.8214.5320.9515.227.7217.5230.028.71
Revenue Growth-27.29%-21.21%-4.9%-30.64%37.67%97.16%-55.94%-41.64%244.6%-
Gross Profit7.9210.897.348.2410.024.39-4.984.4619.75-2.73
Operating Income-24.47-8.45-13.39-9.18-9.40-16.63-31.35-23.43-7.82-31.22
Net Income-23.88-9.24-12.96-8.97-9.24-16.49-31.24-22.90-7.28-30.39
Shares Outstanding3.020.591.841.431.311.271.241.231.030.86
Earnings Per Share-4.50-25.85-7.07-6.30-7.07-13.02-25.20-18.90-7.00-35.70
Operating Cash Flow-35.983.97-8.60-8.39-6.95-9.81-29.80-17.23-3.64-28.23
Capital Expenditures-0.01-0.01-0.08-0.26-0.07-0.07-0.28-0.64-0.26-0.35
Free Cash Flow-35.993.96-8.68-8.64-7.02-9.88-30.08-17.87-3.90-28.58
Cash & Equivalents11.738.0760.6938.9339.9547.1553.5083.8650.4355.27
Total Debt0.074.64--------
Net Cash / Debt11.663.4360.6938.9339.9547.1553.5083.8650.4355.27
Assets18.148.7580.4952.2849.9157.9866.3596.5268.7772.91
Liabilities10.5722.0816.927.154.526.064.947.448.438.55
Book Value7.57-71.6263.5845.1445.3951.9261.4189.0960.3564.36
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Brickell Biotech, Inc.
Country United States
Employees 15
CEO Robert B. Brown

Stock Information

Ticker Symbol BBI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BBI

Description

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead products candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. The company was founded in 2009 and is based in Boulder, Colorado.